Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
???displayArticle.abstract???
The voltage-gated potassium channel Kv1.3 is a novel target for immunomodulation of autoreactive effector memory T cells, which play a major role in the pathogenesis of autoimmune diseases. In this study, the Ts6 and Ts15 toxins isolated from Tityus serrulatus (Ts) were investigated for their immunosuppressant roles on CD4(+) cell subsets: naive, effector (TEF ), central memory (TCM) and effector memory (TEM). The electrophysiological assays confirmed that both toxins were able to block Kv1.3 channels. Interestingly, an extended Kv channel screening shows that Ts15 blocks Kv2.1 channels. Ts6 and Ts15 significantly inhibit the proliferation of TEM cells and interferon-γ production; however, Ts15 also inhibits other CD4(+) cell subsets (naive, TEF and TCM). Based on the Ts15 inhibitory effect of proliferation of all CD4(+) cell subsets, and based on its blocking effect on Kv2.1, we investigated the Kv2.1 expression in T cells. The assays showed that CD4(+) and CD8(+) cells express the Kv2.1 channels mainly extracellularly with TCM cells expressing the highest number of Kv2.1 channels. We also provide in vivo experimental evidence to the protective effect of Ts6 and Ts15 on delayed-type hypersensitivity reaction. Altogether, this study presents the immunosuppressive behaviour of Ts6 and Ts15 toxins, indicating that these toxins could be promising candidates for autoimmune disease therapy. Moreover, this is the first report illustrating the involvement of a novel K(+) channel subtype, Kv2.1, and its distribution in T-cell subsets.
Beeton,
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases.
2006, Pubmed
Beeton,
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases.
2006,
Pubmed
Beeton,
Potassium channels, memory T cells, and multiple sclerosis.
2005,
Pubmed
Beeton,
Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.
2005,
Pubmed
Bjorkdahl,
Characterization of CC-chemokine receptor 7 expression on murine T cells in lymphoid tissues.
2003,
Pubmed
Bond,
Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus.
2006,
Pubmed
Campbell,
CCR7 expression and memory T cell diversity in humans.
2001,
Pubmed
Cerni,
Isolation and characterization of Ts19 Fragment II, a new long-chain potassium channel toxin from Tityus serrulatus venom.
2016,
Pubmed
,
Xenbase
Cerni,
Electrophysiological characterization of Ts6 and Ts7, K⁺ channel toxins isolated through an improved Tityus serrulatus venom purification procedure.
2014,
Pubmed
,
Xenbase
Chandy,
K+ channels as targets for specific immunomodulation.
2004,
Pubmed
Chittajallu,
Regulation of Kv1 subunit expression in oligodendrocyte progenitor cells and their role in G1/S phase progression of the cell cycle.
2002,
Pubmed
Cologna,
Purification and characterization of Ts15, the first member of a new α-KTX subfamily from the venom of the Brazilian scorpion Tityus serrulatus.
2011,
Pubmed
Cologna,
Investigation of the relationship between the structure and function of Ts2, a neurotoxin from Tityus serrulatus venom.
2012,
Pubmed
,
Xenbase
DeCoursey,
Voltage-gated K+ channels in human T lymphocytes: a role in mitogenesis?
,
Pubmed
Dixon,
Quantitative analysis of potassium channel mRNA expression in atrial and ventricular muscle of rats.
1994,
Pubmed
Dixon,
Potassium channel mRNA expression in prevertebral and paravertebral sympathetic neurons.
1996,
Pubmed
Drewe,
Distinct spatial and temporal expression patterns of K+ channel mRNAs from different subfamilies.
1992,
Pubmed
,
Xenbase
Edman,
A protein sequenator.
1967,
Pubmed
Fadool,
Modulation of olfactory bulb neuron potassium current by tyrosine phosphorylation.
1998,
Pubmed
Farber,
Human memory T cells: generation, compartmentalization and homeostasis.
2014,
Pubmed
Feske,
A severe defect in CRAC Ca2+ channel activation and altered K+ channel gating in T cells from immunodeficient patients.
2005,
Pubmed
Frech,
A novel potassium channel with delayed rectifier properties isolated from rat brain by expression cloning.
1989,
Pubmed
,
Xenbase
Gattinoni,
Paths to stemness: building the ultimate antitumour T cell.
2012,
Pubmed
Grunnet,
The voltage-gated potassium channel subunit, Kv1.3, is expressed in epithelia.
2003,
Pubmed
Gutman,
International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels.
2005,
Pubmed
Gwack,
Signalling to transcription: store-operated Ca2+ entry and NFAT activation in lymphocytes.
2007,
Pubmed
Henningsen,
A sensitive delayed-type hypersensitivity model in the rat for assessing in vivo cell-mediated immunity.
1984,
Pubmed
Hommes,
Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease.
2006,
Pubmed
Hou,
Physiological role of Kv1.3 channel in T lymphocyte cell investigated quantitatively by kinetic modeling.
2014,
Pubmed
Hu,
Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes.
2007,
Pubmed
Kuras,
Modulation of Kv1.3 channels by protein kinase A I in T lymphocytes is mediated by the disc large 1-tyrosine kinase Lck complex.
2012,
Pubmed
Le Deist,
A primary T-cell immunodeficiency associated with defective transmembrane calcium influx.
1995,
Pubmed
Lewis,
Calcium signaling mechanisms in T lymphocytes.
2001,
Pubmed
Li,
The role of voltage-gated potassium channels Kv2.1 and Kv2.2 in the regulation of insulin and somatostatin release from pancreatic islets.
2013,
Pubmed
Liman,
Subunit stoichiometry of a mammalian K+ channel determined by construction of multimeric cDNAs.
1992,
Pubmed
,
Xenbase
Liu,
Modulation of Kv channel expression and function by TCR and costimulatory signals during peripheral CD4(+) lymphocyte differentiation.
2002,
Pubmed
MacDonald,
Voltage-dependent K(+) channels in pancreatic beta cells: role, regulation and potential as therapeutic targets.
2003,
Pubmed
MacDonald,
Inhibition of Kv2.1 voltage-dependent K+ channels in pancreatic beta-cells enhances glucose-dependent insulin secretion.
2002,
Pubmed
Middleton,
Substitution of a single residue in Stichodactyla helianthus peptide, ShK-Dap22, reveals a novel pharmacological profile.
2003,
Pubmed
,
Xenbase
Miljanich,
Ziconotide: neuronal calcium channel blocker for treating severe chronic pain.
2004,
Pubmed
Mizuguchi,
Type I interferons as immunoregulatory molecules; implications for therapy in experimental autoimmune uveoretinitis.
2002,
Pubmed
Nicolaou,
Differential calcium signaling and Kv1.3 trafficking to the immunological synapse in systemic lupus erythematosus.
2010,
Pubmed
Novello,
TsTX-IV, a short chain four-disulfide-bridged neurotoxin from Tityus serrulatus venom which acts on Ca2+-activated K+ channels.
1999,
Pubmed
Opie,
The discovery of captopril: from large animals to small molecules.
1995,
Pubmed
Ortiz,
Scorpion venom components as potential candidates for drug development.
2015,
Pubmed
Pappone,
Blockers of voltage-gated K channels inhibit proliferation of cultured brown fat cells.
1993,
Pubmed
Peigneur,
A gamut of undiscovered electrophysiological effects produced by Tityus serrulatus toxin 1 on NaV-type isoforms.
2015,
Pubmed
,
Xenbase
Pimenta,
Covalent structure and some pharmacological features of native and cleaved alpha-KTx12-1, a four disulfide-bridged toxin from Tityus serrulatus venom.
2003,
Pubmed
Pucca,
Revealing the Function and the Structural Model of Ts4: Insights into the "Non-Toxic" Toxin from Tityus serrulatus Venom.
2015,
Pubmed
,
Xenbase
Pucca,
Electrophysiological characterization of the first Tityus serrulatus alpha-like toxin, Ts5: Evidence of a pro-inflammatory toxin on macrophages.
2015,
Pubmed
Rashid,
A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases.
2014,
Pubmed
Scarborough,
Development of eptifibatide.
1999,
Pubmed
Schlichter,
Properties of K+ and Cl- channels and their involvement in proliferation of rat microglial cells.
1996,
Pubmed
Schmitz,
Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.
2005,
Pubmed
Skurkovich,
Anti-interferon-gamma antibodies in the treatment of autoimmune diseases.
2003,
Pubmed
Titus,
A simple and effective method to assess murine delayed type hypersensitivity to proteins.
1981,
Pubmed
Trimmer,
Expression of Kv2.1 delayed rectifier K+ channel isoforms in the developing rat brain.
1993,
Pubmed
Tytgat,
A unified nomenclature for short-chain peptides isolated from scorpion venoms: alpha-KTx molecular subfamilies.
1999,
Pubmed
Ueyama,
Kv1.3 blockers ameliorate allergic contact dermatitis by preferentially suppressing effector memory T cells in a rat model.
2013,
Pubmed
Vicente,
Differential voltage-dependent K+ channel responses during proliferation and activation in macrophages.
2003,
Pubmed
Wulff,
Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840.
2010,
Pubmed
Wulff,
Voltage-gated potassium channels as therapeutic targets.
2009,
Pubmed
Wulff,
K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity.
2004,
Pubmed
Wulff,
The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS.
2003,
Pubmed